Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICI-HIPET: HIPEC + Tislelizumab in Advanced Ovarian Cancer
NCT07068178Phase 2Not yet recruiting
- Start
- Aug 2025
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in ovarian cancer. Primary endpoint: R0 Resection Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07068178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068178.